Phase-1 Executions

Execution Boundary

Phase-1 execution for Precision Clinical Communication (PCC) operates strictly within a non-clinical, non-operational simulation environment.

All activities are conducted using simulated scenarios and synthetic or de-identified content.

Phase-1 execution does not:

  • Deliver messages to patients, families, or caregivers

  • Participate in clinical care or clinical decision-making

  • Integrate with EHR systems or operational workflows

  • Generate autonomous patient-facing communication

  • Use live patient data or real-time clinical information

  • License, transfer, or commercialize intellectual property

  • Engage in venture formation, product deployment, or market activity

Any clinical use, workflow integration, institutional adoption, or commercialization occurs only outside the Studio boundary under separate clinical, informatics, privacy, and compliance governance.

Representative Phase-1 PCC Scope

Phase-1 execution evaluates whether communication can be safely and effectively adapted to different audiences and clinical contexts under controlled conditions.

Representative areas of evaluation include:

  • Generating multiple communication variants for the same clinical scenario

  • Adapting messages for literacy level, language, tone, and complexity

  • Differentiating communication for patient and caregiver roles

  • Evaluating clarity, appropriateness, and contextual alignment

  • Assessing knowledge transfer and identifying comprehension gaps

All evaluation occurs within simulated use cases. Phase-1 execution is intended to mature communication capabilities prior to any clinical or operational consideration.

What Execution Looks Like

Within the Studio, Phase-1 execution includes:

  • Developing and refining audience-specific communication models

  • Testing alternative message structures and rhetorical approaches

  • Simulating response scenarios to evaluate understanding

  • Identifying communication risks, failure modes, and unintended effects

  • Iteratively improving content based on structured review

  • Documenting limitations, safeguards, and governance requirements

Execution is iterative and evidence-driven. Approaches may be refined, redesigned, or discontinued based on findings.

Relationship to Intellectual Property

Phase-1 PCC execution is conducted within DLEV Studio as part of the disciplined maturation of proprietary communication system architectures held by Grasso & Co., LLC.

Within the Studio, PCC is treated as a developing capability subject to validation, modification, or discontinuation based on evidence generated through structured evaluation.

Phase-1 execution does not imply:

  • Clinical readiness

  • Institutional endorsement

  • Publication status

  • Commercial availability

Inquiry

For research or institutional inquiry consistent with Phase-1 execution scope:

engagement@dlevstudio.com

Execution of Architected Systems Under Governed Simulation

Definition: Phase-1 Execution

Phase-1 execution refers to the controlled development and evaluation of system capabilities within a governed simulation environment prior to any clinical, operational, or institutional use.

At this stage, all activity is non-clinical, non-operational, and non-commercial. No patient-facing deployment, workflow integration, or institutional implementation occurs. System capabilities may be refined, redesigned, or discontinued based on findings generated through disciplined evaluation. Any downstream clinical use, operational integration, or institutional adoption occurs only under separate, explicitly defined governance.

© 2026 Grasso & Co., LLC. All rights reserved.
DLEV Studio is an internal, non-commercial execution and evaluation initiative of Grasso & Co., LLC.
This site is informational only and does not constitute an offer, solicitation, or agreement.